Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ESR1 | P03372 | 5/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9522826 | 0.98 | KDM4E (0.38) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL5210717 | 0.84 | KDM4E (0.41) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL867987 | 0.80 | PPARG (0.43) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL5513086 | 0.76 | KDM4E (0.43) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL14116463 | 0.75 | KDM4E (0.42) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL868550 | 0.75 | KDM4E (0.46) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| Bromide SCHEMBL14332016 | 0.74 | KDM4E (0.39) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL23570309 | 0.73 | KDM4E (0.41) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL23396073 | 0.73 | KDM4E (0.41) | KDM4EL3MBTL1ESR1ESR2HRH3 | |
| SCHEMBL27515092 | 0.72 | KDM4E (0.43) | KDM4EL3MBTL1ESR1ESR2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993773-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2015-03-31 | — | — | US | disclosed |
| EP-2364971-B1 | 2,5-Disubstituted pyridines for the preparation of 2-substituted 5-(1-alkylthio)-alkylpyridines | DOW AGROSCIENCES LLC (US) | 2014-04-30 | — | — | EP | disclosed |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2014-03-27 | — | — | US | disclosed |
| US-8445685-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2013-05-21 | — | — | US | disclosed |
| US-8173816-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2012-05-08 | — | — | US | disclosed |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-29 | — | — | US | disclosed |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2011-01-27 | — | — | US | disclosed |
| US-7863300-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2011-01-04 | — | — | US | disclosed |
| US-7671207-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2010-03-02 | — | — | US | disclosed |
| US-7465801-B2 | Process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-16 | — | — | US | disclosed |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED (IN) | 2008-01-03 | — | — | US | disclosed |
| EP-1521753-B1 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LTD (IN) | 2007-09-05 | — | — | EP | disclosed |
| US-20060167061-A1 | Novel process to prepare pioglitazone via several novel intermediates | CADILA HEALTHCARE LIMITED | 2006-07-27 | — | — | US | disclosed |
| EP-1521753-A2 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LTD. (IN) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007490-A2 | A PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL INTERMEDIATES. | CADILA HEALTHCARE LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004446-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | KDM4E 4174/4885L3MBTL1 4871/4885ESR1 2614/4885 |
| US-20140088127-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | KDM4E 3954/4885L3MBTL1 4864/4885ESR1 2572/4885 |
| US-20080300282-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | KDM4E 3954/4885L3MBTL1 4864/4885ESR1 2572/4885 |
| US-20120077848-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | KDM4E 3954/4885L3MBTL1 4864/4885ESR1 2572/4885 |
| US-20110021576-A1 | NOVEL PROCESS TO PREPARE PIOGLITAZONE VIA SEVERAL NOVEL INTERMEDIATES | PPARD, PPARG, PPARA | KDM4E 3954/4885L3MBTL1 4864/4885ESR1 2572/4885 |
| US-20060167061-A1 | Novel process to prepare pioglitazone via several novel intermediates | PPARD, PPARG, PPARA | KDM4E 3954/4885L3MBTL1 4864/4885ESR1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.